Johnson & Johnson
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson Oncology Therapeutic Area Total by Year
Oncology Therapeutic Area Total — Worldwide sales ($M) ($M)
Johnson & Johnson Oncology Therapeutic Area Total: $25,380M in FY2025, up 22.1% from a year earlier. That is the highest of the 10 years on record here.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-11) ↗
Reported in Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Oncology Therapeutic Area Total — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 28, 2025 | 25,380 | +22.1% | Form 10-K (filed 2026-02-11) ↗ |
| FY2024 | Dec 29, 2024 | 20,781 | +17.7% | Form 10-K (filed 2026-02-11) ↗ |
| FY2023 | Dec 31, 2023 | 17,661 | +10.5% | Form 10-K (filed 2026-02-11) ↗ |
| FY2022 | Jan 1, 2023 | 15,983 | +9.9% | Form 10-K (filed 2025-02-13) ↗ |
| FY2021 | Jan 2, 2022 | 14,548 | +17.6% | Form 10-K (filed 2024-02-16) ↗ |
| FY2020 | Jan 3, 2021 | 12,367 | +15.7% | Form 10-K (filed 2023-02-16) ↗ |
| FY2019 | Dec 29, 2019 | 10,692 | +8.6% | Form 10-K (filed 2022-02-17) ↗ |
| FY2018 | Dec 30, 2018 | 9,844 | +35.6% | Form 10-K (filed 2021-02-22) ↗ |
| FY2017 | Dec 31, 2017 | 7,258 | +25.0% | Form 10-K (filed 2019-02-20) ↗ |
| FY2016 | Jan 1, 2017 | 5,807 | – | Form 10-K (filed 2019-02-20) ↗ |
Breakdown
What makes up oncology Therapeutic Area Total
- Oncology Therapeutic Area Total — U.S. sales ($M)13,659 · FY2025
- Oncology Therapeutic Area Total — International sales ($M)11,721 · FY2025
- Oncology Therapeutic Area Total — Worldwide reported growth YoY (%)22.1% · FY2025
- Oncology Therapeutic Area Total — Worldwide operational (constant-currency) growth YoY (%)20.9% · FY2025
- DARZALEX (daratumumab) — Worldwide sales ($M)14,351 · FY2025
- ERLEADA (apalutamide) — Worldwide sales ($M)3,574 · FY2025
- CARVYKTI (ciltacabtagene autoleucel) — Worldwide sales ($M)1,887 · FY2025
- IMBRUVICA (ibrutinib) — Worldwide sales ($M)2,823 · FY2025
- RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — Worldwide sales ($M)734 · FY2025
- TECVAYLI (teclistamab) — Worldwide sales ($M)670 · FY2025
- TALVEY (talquetamab) — Worldwide sales ($M)463 · FY2025
- ZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — Worldwide sales ($M)502 · FY2025
- VELCADE (bortezomib) [reported separately through FY2020Q4] — Worldwide sales ($M)408 · FY2020
- Other Oncology medicines — Worldwide sales ($M)376 · FY2025
Cite this data
StockData. (2026). Johnson & Johnson Oncology Therapeutic Area Total ($M), annual FY2016–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/ta-oncology
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.